Practical tips for the diagnosis, evaluation and treatment of a spectrum of conditions commonly encountered in a rheumatology practice are offered.
The State of Clinical Science for Pediatric Rheumatology in 2021
ACR Convergence 2021—The Pediatric Rheumatology Year in Review began with a fascinating talk by Mara Becker, MD, MSCE, a professor of Pediatrics and vice chair of faculty at Duke University School of Medicine, Durham, N.C. Dr. Becker began by describing her search strategy to select high-yield clinical science publications in pediatric rheumatology from the past…
Experts Discuss Blood Disorders Commonly Seen in Lupus Patients
ACR CONVERGENCE 2021—Hematologic abnormalities are common in systemic lupus erythematosus (SLE), whether due to SLE itself or something else. As rheumatology professionals, we are routinely challenged by the management of cytopenias in our SLE patients. At the ACR’s annual meeting in 2021, two hematologists shared expert advice regarding common hematologic manifestations of SLE. Michael B….
Speak Out Rheumatology: Telerheumatology for Improving Accessibility
An early adopter gives her take on telerheumatology.
Business Rheum: What to Expect from New MVP Measures
The new rheumatology-specific Merit-Based Incentive Payment System Value Pathway will focus on measures that most rheumatologists already track. The model should streamline reporting and better target quality improvements.
The ACR Thanks 2021 RheumPAC Matching Campaign Donors
With a record-high 46 first-time contributors, this year’s matching campaign raised more than $26,000 from members and another $17,000 from volunteer leaders who made a pledge for each donor, advancing advocacy efforts on behalf of rheumatology.
The Great Debate: Belimumab vs. Voclosporin in Lupus Nephritis
ACR Convergence 2021—The Great Debate at the meeting sparked a thoughtful discussion on the future of lupus nephritis treatment strategies, with experts saying clinicians should be open to new ways of approaching patient care. In the past year, approvals of the monoclonal antibody belimumab and the calcineurin inhibitor voclosporin for use in lupus nephritis (when…
HCQ/CQ May Increase the Risk of Cardiovascular Events
A special article in the December issue of Arthritis & Rheumatology summarizes the current understanding of the cardiac toxicity of HCQ and CQ.
Advances in Connective Tissue Disease-Associated Interstitial Lung Disease
ACR Convergence 2021—The past year has been an exciting time for researchers and clinicians focused on the topic of connective tissue disease-associated interstitial lung disease (CTD-ILD), with advances in our understanding of these disorders and newly approved medications for their treatment. At the ACR Convergence 2021 annual Review Course, Kristin Highland, MD, MSCR, director of…
FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting
ACR Convergence 2021—The recent Boxed Warning requirement applied to three Janus kinase (JAK) inhibitors, cautioning doctors and patients about several major risks in patients with rheumatoid arthritis, came only after rigorous data collection and careful consideration of the risks and the benefits, U.S. Food & Drug Administration (FDA) officials said in November at ACR Convergence…
- « Previous Page
- 1
- …
- 115
- 116
- 117
- 118
- 119
- …
- 809
- Next Page »